Pfizer Expands Collaboration with Flagship Pioneering, Adding Ampersand Biomedicines and Montai Therapeutics

Partnership Expansion: Pfizer has expanded its strategic partnership with Flagship Pioneering by adding two more companies:
Ampersand Biomedicines and Montai Therapeutics[2][3][5].

Focus Areas:
The collaborations aim to identify targeted molecules for the treatment of obesity and non-small cell lung cancer (NSCLC), leveraging Pfizer's expertise in early discovery and development[2][3].

Ampersand Biomedicines:
Ampersand will use its AND platform to identify programmed biologics for obesity-related targets[2].

Montai Therapeutics:
Montai will utilize its CONECTA AI platform to identify small molecules directed at a potential NSCLC-related target[2].

Innovation Supply Chain Partnership:
This partnership is part of Flagship's Innovation Supply Chain model, which aims to unite Flagship's ecosystem of diverse bioplatforms with Pfizer's disease and therapeutic development expertise to accelerate drug development[1][2].

Previous Collaborations:
The new agreements follow previously announced collaborations with ProFound Therapeutics and Quotient Therapeutics, marking continued momentum for the partnership[2][3].